Marrek, Inc.

Marrek, Inc. is a leading provider of advanced cardiac imaging and analysis technologies for atrial fibrillation (AFib) treatment planning. The company operates Merisight, a proprietary image analysis service that leverages non-invasive cardiac MRI to quantify left atrium tissue damage and scar formation in AFib patients. By providing physicians with precise pre-ablation tissue mapping and post-ablation scar analysis, Merisight enables personalized treatment selection and improves ablation success rates beyond the current 50% baseline. The service integrates seamlessly with existing ablation mapping systems and includes protocol optimization, secure image sharing, expert processing, and comprehensive clinical support. Marrek's mission is to transform AFib treatment outcomes through data-driven decision support and tissue characterization.